Home / Health / Eli Lilly Sues Over Counterfeit Weight-Drug
Eli Lilly Sues Over Counterfeit Weight-Drug
12 Aug
Summary
- Eli Lilly is suing six companies for illegally selling unapproved weight-loss drug versions.
- The lawsuits target firms marketing counterfeit retatrutide for research or medical spa use.
- The drugmaker seeks to protect consumers and its own drug's reputation from illicit products.
Eli Lilly has initiated legal proceedings against six companies for the illicit sale of its experimental weight-loss drug, retatrutide. This action marks the beginning of a broader effort to dismantle a significant black market that has developed around the compound.
The drug, which is still undergoing clinical trials and has not been approved by the FDA, has gained substantial social media attention. Despite federal law prohibiting the sale of unapproved drugs, numerous telehealth firms, clinics, and online vendors have begun offering versions of retatrutide.
Eli Lilly's lawsuits specifically target companies like Astra Peptides, Legendary Peptides, Texas Peptides, and Lone Star Peptide, which market the substance for research purposes, as well as Aesthetic Envy, a California med spa, and Striker Pharmacy. These entities are accused of supplying imitation retatrutide, potentially manufactured overseas.
The drugmaker states that these unvetted products pose risks to consumers and threaten the integrity of retatrutide. Eli Lilly anticipates seeking regulatory approval for the drug in early 2027, following promising trial results for obesity and type 2 diabetes.
